Leaders of the NIH funded Molecular Transducers of Physical Activity (MoTrPAC) study meet at UCI Pediatric Exercise and Genomics Research Center (PERC) and the ICTS for final approval to launch participant recruitment in the most ambitious study of the health effects of exercise in children ever undertaken. PERC was selected as the only pediatric clinical trial site that, over the next 3-5 years will enroll more than 300 children and adolescents. MoTrPAC will employ cutting-edge genomics, metabolomics, proteomics, and cardiopulmonary exercise testing to unravel the mechanisms that link exercise to health. The knowledge gained will then transform the use of exercise to enhance health using both therapeutic and diagnostic innovations. In addition to the children and adolescents to be studied at PERC, MoTrPAC anticipates enrolling more than 2,500 adults across all ages in its clinical sites across the US. NIH and study leaders gave an enthusiastic “thumbs-up” to PERC leader and MoTrPAC Principal Investigator Dr. Shlomit Aizik. Enrollment is set to begin in October.
